Friday, October 30, 2026 · Edition updated 6:00 AM ETFRI, OCT 30 · 6 AM ET editionNext edition in Next --:--:--

Review of how the FOXO4 protein may guard cells against damage and aging

A summary of earlier studies · Antioxidants (Basel, Switzerland) · Jul 28, 2026

What this means

This review sorted past studies on FOXO4 by how directly they tested it. Some links are well supported, but many antioxidant effects are still based on related proteins.

Plain-English summary written by an AI model from the abstract. The original is below.

Tested inSummary of earlier studies
Who it was tested in
A review of 89 publications, including 18 studies directly on FOXO4
Kind of research
A summary of earlier studies

The science

Original title
FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting.
Authors
Mateescu DM, Gavrilescu DM, Marinescu AR et al.
Journal
Antioxidants (Basel, Switzerland)
Published
Jul 28, 2026
Study type
Review

Abstract

(1) Background: Reactive oxygen species (ROS) act as physiological signaling mediators but contribute to oxidative damage, cellular dysfunction, and age-related disease when redox homeostasis fails. Forkhead box O4 (FOXO4) has emerged as a redox-sensitive regulator linking stress adaptation, antioxidant defense, and cellular senescence. This structured narrative review critically evaluates which redox- and aging-related conclusions are supported directly for FOXO4 and which remain inferred from other FOXO isoforms. (2) Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to May 2026; Google Scholar was used only for supplementary citation tracking and did not contribute a separate platform-level count. Of 420 records, 300 remained after deduplication, 110 full texts were assessed, and 89 publications were retained. FOXO4-related evidence was classified as directly FOXO4-specific (n = 18), FOXO-family/conserved (n = 24), or extrapolated predominantly from FOXO1/FOXO3/DAF-16 (n = 20); 27 contextual publications on redox biology, senescence, disease, and NRF2 were tracked separately. (3) Results: The strongest FOXO4-specific evidence supports three mechanistic axes: cysteine-dependent redox sensing, stress-regulated nuclear trafficking and coactivator engagement through transportin-1 and p300/CBP, and FOXO4-p53-mediated survival of senescent cells. By contrast, direct FOXO4 regulation of commonly cited antioxidant targets, including SOD2, catalase, sestrins, and GADD45, remains insufficiently demonstrated and is inferred mainly from FOXO3 or broader FOXO-family studies. FOXO4-DRI has shown senolytic activity in preclinical models, including vascular endothelium, but has not been clinically validated. (4) Conclusions: FOXO4 is a redox-responsive transcriptional regulator with well-supported roles in cysteine-based signaling and senescent-cell survival, whereas its target-gene-level antioxidant program remains incompletely resolved. Clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance.

Read it on PubMed ↗

Mateescu DM, Gavrilescu DM, Marinescu AR et al. FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel, Switzerland). 2026. doi:10.3390/antiox15070842. PMID: 42510573. https://pubmed.ncbi.nlm.nih.gov/42510573/

Related research

Study · JACS Au · Oct 29, 2026

New fluorescent sensor detects cells aging from cancer and lung drugs

Researchers built a glowing probe that lights up only in certain aged cells. It may help scientists track these cells in living animals, but this is early lab work.

Study · Neuro-oncology · Oct 29, 2026

Mixing a senescence-clearing drug with trametinib slowed glioma regrowth in mice

Researchers found a drug combination that cleared aging-like tumour cells in mice and slowed regrowth. This does not show the combination would work the same way in children.

AnimalsStudy · Molecular metabolism · Oct 29, 2026

A vaccine-style treatment in mice eased diabetes signs and aged cell markers

Mice given a treatment aimed at a virus-like gene showed less weight gain and better blood sugar control. This study was in mice and cells, so it does not show the same would happen in people.

Summary of earlier studiesReview · Aging cell · Oct 28, 2026

Aging cells that support stem cells may disrupt them through chemical signals

This is a review that pulls together older and newer studies. It proposes a model, but it does not show that the model is true.

Preprint · bioRxiv · Oct 28, 2026

Cx43 protein may boost breast cancer drug response in lab tests

Researchers studied a protein called Cx43 that helps cells talk to each other. They found it may help a breast cancer drug slow tumor growth. This early work is not yet checked by other scientists, so it does not show this would help people.

Study · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Oct 28, 2026

A new vaccine clears aging cells in mice and may extend lifespan

Researchers made a vaccine aimed at old, worn-out cells called senescent cells. In mice, it cleared some of these cells and helped metabolism. This is early work, so it does not show the vaccine would help people.

See all research on Senolytics →

Report a problem